Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on March 19, 2015. The report announces financial results for the fourth quarter and the full fiscal year ended December 31, 2014. Note: The request metadata references "Larimar Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Zafgen, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It serves only as a notification that results for Q4 and FY 2014 have been announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability.
Investor Verification Checklist
- Verify the correct registrant name (Zafgen, Inc. vs. Larimar Therapeutics, Inc.) in the context of your investment thesis.
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for Q4 and FY 2014.
- Confirm the specific details of the financial results and any forward-looking statements in the referenced press release.